Fig. 3From: TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth modelEnzalutamide inhibits the bone tumor growth. Enzalutamide treatment started when VCaP scr shRNA and VCaP ERG shRNA tumors reached similar size as per luciferase signal in the bone tumors. a Intratibial tumor growth of luciferase expressing VCaP scr shRNA and VCaP ERG shRNA cells and treatment with vehicle control or enzalutamide. b Comparison of tumor growth of vehicle treated VCaP scr shRNA and VCaP ERG shRNA tumors. c Comparison of tumor growth of enzalutamide treated VCaP scr shRNA and VCaP ERG shRNA tumors. d Luciferase imaging of bone tumorsBack to article page